Jeffrey Hunter, MD
Internal Medicine · Winter Haven, FLNPI 1528063369
Payments from drug & device makers
Across 448 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$978
- Amgen$777
- Novo Nordisk$764
- Pfizer$695
- Novartis$573
- Merck$562
- plus $4K from 32 others
What the payments were for
- Food & beverage$8,048100%
- Education$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $978 |
| Amgen | 53 | $777 |
| Novo Nordisk | 44 | $764 |
| Pfizer | 44 | $695 |
| Novartis | 33 | $573 |
| Merck | 31 | $562 |
| Johnson & Johnson | 12 | $430 |
| Boehringer Ingelheim | 22 | $400 |
| AbbVie(2 entities) | 21 | $392 |
| Lilly USA, LLC | 19 | $336 |
| GSK | 12 | $222 |
| Bayer | 10 | $219 |
| Astellas Pharma US Inc | 14 | $217 |
| Dexcom, Inc. | 9 | $169 |
| Mylan Specialty L.p. | 10 | $168 |
| Sanofi-aventis U.S. LLC | 9 | $148 |
| Esperion Therapeutics, Inc. | 7 | $133 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $115 |
| Exact Sciences | 6 | $99 |
| Otsuka America Pharmaceutical, Inc. | 4 | $87 |
| Boston Scientific | 3 | $68 |
| Abbott | 3 | $65 |
| Amarin Pharma, Inc. | 4 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $61 |
| Eisai Inc. | 3 | $60 |
| Biohaven Pharmaceuticals, Inc. | 2 | $50 |
| Jazz Pharmaceuticals Inc. | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Shield Therapeutics Inc | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Tolmar, Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Nevro Corp. | 1 | $14 |
| Nalpropion Pharmaceuticals LLC | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $12 |
| Mannkind Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,083 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 207 | $207,983 |
| XareltoRivaroxaban | 171 | $199,430 |
| MounjaroTirzepatide | 178 | $196,413 |
| JardianceEmpagliflozin | 89 | $118,267 |
| FarxigaDapagliflozin Propanediol | 95 | $112,156 |
| OzempicSemaglutide | 88 | $97,507 |
| EntrestoSacubitril/Valsartan | 46 | $64,281 |
| OtezlaApremilast | 11 | $52,925 |
| TrulicityDulaglutide | 33 | $45,116 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $44,423 |
| JanuviaSitagliptin Phosphate | 40 | $41,884 |
| RybelsusSemaglutide | 19 | $30,039 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $29,953 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 26 | $22,051 |
| MyrbetriqMirabegron | 22 | $21,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $336 | $241,529211 claims |
| PfizerEliquis | $695 | $207,983207 claims |
| Johnson & JohnsonXarelto | $430 | $199,430171 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $978 | $131,914111 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $400 | $127,691101 claims |
| Novo NordiskOzempic, Rybelsus | $764 | $127,546107 claims |
| MerckJanuvia, Janumet Xr, Belsomra | $562 | $69,47479 claims |
| NovartisEntresto | $573 | $64,28146 claims |
| AmgenOtezla | $777 | $52,92511 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $222 | $49,55277 claims |
| Astellas Pharma US IncMyrbetriq | $217 | $21,81722 claims |
| AbbVieSynthroid | $392 | $5,01573 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Winter Haven
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.